Abstract
The renin angiotensin aldosterone system (RAAS) inhibitors induce an incomplete blockade of the system at different steps. Recently, the dual RAAS therapy is emerging in clinical practice, although there is a lack of evidence on safety and efficacy for this combination in several cardiovascular diseases. In this review, we evaluated the advantages and disadvantages of dual RAAS blockade in hypertension, proteinuric renal disease, heart failure and ischaemic heart disease. The role of DRIs in combination with ACEI or ARBs is promising, but still needs further studies. On the basis of the clinical outcomes and safety data the recommendations guidelines have not confirmed indications to dual RAAS blockade in essential hypertension treatment, heart failure and ischemic heart disease. Only proteinuric nephropaties and resistant hypertension may represent possible indications to dual RAAS blockade. Actually, rational combinations of either an ACEI or ARB or DRI with other classes of antihypertensives offer best solutions.
Keywords: Renin-angiotensin-aldosterone system, hypertension, heart failure, proteinuria, RAAS therapy, cardiovascular diseases, ischaemic heart disease, antihypertensives, nephropaties, aliskiren
Current Pharmaceutical Design
Title: Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?
Volume: 18 Issue: 7
Author(s): Franco Veglio, Elisabetta Puglisi, Alberto Milan and Paolo Mulatero
Affiliation:
Keywords: Renin-angiotensin-aldosterone system, hypertension, heart failure, proteinuria, RAAS therapy, cardiovascular diseases, ischaemic heart disease, antihypertensives, nephropaties, aliskiren
Abstract: The renin angiotensin aldosterone system (RAAS) inhibitors induce an incomplete blockade of the system at different steps. Recently, the dual RAAS therapy is emerging in clinical practice, although there is a lack of evidence on safety and efficacy for this combination in several cardiovascular diseases. In this review, we evaluated the advantages and disadvantages of dual RAAS blockade in hypertension, proteinuric renal disease, heart failure and ischaemic heart disease. The role of DRIs in combination with ACEI or ARBs is promising, but still needs further studies. On the basis of the clinical outcomes and safety data the recommendations guidelines have not confirmed indications to dual RAAS blockade in essential hypertension treatment, heart failure and ischemic heart disease. Only proteinuric nephropaties and resistant hypertension may represent possible indications to dual RAAS blockade. Actually, rational combinations of either an ACEI or ARB or DRI with other classes of antihypertensives offer best solutions.
Export Options
About this article
Cite this article as:
Veglio Franco, Puglisi Elisabetta, Milan Alberto and Mulatero Paolo, Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436566
DOI https://dx.doi.org/10.2174/138161212799436566 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Left Ventricular Hypertrophy Beyond Hemodynamics: Genetic, Metabolic and Hormonal Factors
Current Hypertension Reviews Pharmacological and Lifestyle Factors Modulating Serum Paraoxonase-1 Activity
Mini-Reviews in Medicinal Chemistry Plasmid DNA-based Gene Transfer with Ultrasound and Microbubbles
Current Gene Therapy Present Insights on Cardiomyopathy in Diabetic Patients
Current Diabetes Reviews Correlation of Waist to Calf Circumference Ratio and Carotid Intima-Media Thickness in Diabetes Mellitus
Current Diabetes Reviews Anthocyanins as a Potential Therapy for Diabetic Retinopathy
Current Medicinal Chemistry Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design Developments of Anticoagulants and New Agents with Anti-Coagulant Effects in Deep Vein Thrombosis
Mini-Reviews in Medicinal Chemistry Developing Stress Assessment forms for Thai Cancer Patients: The Thai Version of the Modified Symptoms of Stress Inventory (Modified SOSI)
Current Psychiatry Research and Reviews Dimensional Assessment of Hypochondriacal Fears and Beliefs
Current Psychiatry Reviews Interactions of Dietary Flavonoids with Proteins: Insights from Fluorescence Spectroscopy and Other Related Biophysical Studies
Current Drug Metabolism Withdrawal Notice: Design and Analysis of Optimization and Tuning in Data Warehouses Using Bitmap Indexes
Recent Advances in Computer Science and Communications Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Involvement of the Serotonergic System in Cognitive and Behavioral Symptoms of Alzheimers Disease
Current Psychiatry Reviews Meet Our Editorial Board Member
Current Traditional Medicine Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design Apolipoprotein E Knockout Models
Current Pharmaceutical Design Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol
Current Drug Metabolism Intestinal Fatty acid Absorption
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)